Rituxan (rituximab) - Roche
NODULAR LYMPHOCYTE-PREDOMINANT HODGKIN LYMPHOMA: A 10-YEAR SINGLE-CENTER RETROSPECTIVE ANALYSIS OF CLINICAL CHARACTERISTICS AND OUTCOMES (SIE 2026) - Oct 6, 2026 - Abstract #SP051; "Outcomes were also com- pared between pts treated with R-ABVD and those receiving R-CHOP or similar regimens...DP was associated with inferior PFS, without differ- ences in OS. No significant differences emerged between R- -CHOP and R-ABVD, likely reflecting treatment selection based on disease characteristics" 
Retrospective data • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Large B Cell Lymphoma • Lymphoma • Nodular Lymphocyte Predominant Hodgkin Lymphoma • Non-Hodgkin's Lymphoma
https://manage.ercongressi.it/storage/ercongressi/article/pdf/291/14496-SIE2026%20-%20abstract%20book.pdf
 
V. Berti1,2; S. Jance1,2; A. Bernardelli3; C. Genua1; A. Harb1; M. Krampera1; C. Visco1
 
Oct 6, 2026
 
Prev Next